Record

Gilead Sciences as of November 8, 2026 · AsOf

organization

Gilead Sciences

Gilead Sciences is an American biopharmaceutical company, headquartered in Foster City. It reported revenue of $29.44B for the period ended December 31, 2025.

CFO: Andrew D. Dickinson sec.gov
Headquarters: Foster City sec.gov
Revenue: $29.44B to 2025-12-31 sec.gov
Ticker: GILD · Nasdaq sec.gov

Read the record as of a date

Compare the record on two dates →

State as of 2026-11-08

7 assertedThe record stands behind this value for the day asked: two independent sources agree, or a primary source states it (alone, at confidence 0.7 or more). Everything else stays on the record, labelled.More in About → facts

Gilead Sciences: state as of 2026-11-08, one row per fact with its value, date, confidence and sources
fact	value	valid fromThe day the value took effect, not the day it was published. A period figure (a year's revenue) is dated at the period's end.More in About →	confidenceHow well the sources support the value, from 0 to 1. A single primary source is asserted from 0.7; nothing below 0.5 is asserted; a dead or disagreeing source lowers it.More in About →	sourcesPrimary: the entity's own filing, feed or site. Secondary: a publisher reporting it. Each claim links every source it has, with the passage that states the value where one was read.More in About →

Latest

2 dated events · full timeline →

2026-02-22 · agreementagreement

sec.gov

2024-02-11 · agreementagreement

sec.gov

Financials

latest period on record · change vs prior year

Revenue

$29.44B

2025-12-31+2.4%

every revenue figure →

Net income

$8.51B

2025-12-31+1672.9%

every net income figure →

Operating income

$10.02B

2025-12-31+503.0%

every operating income figure →

Total assets

$51.41B

2026-09-30-12.2%

Cash

$5.41B

2022-12-31+1.4%

latest on record; no newer figure held

As reported in the linked filings, which may be restated. Not investment advice.

State changes since 2026-05-12

18 changes · supersededA later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.More in About →

2026-10-23 · shares outstandingshares outstanding

sec.gov: 1 source for shares outstanding, claim clm_3ADDE79BC725

2026-07-31 · shares outstandingshares outstanding

sec.gov: 1 source for shares outstanding, claim clm_87D3256ADA54 replaced by →

2026-09-30 · quarterly net incomequarterly net income

About this record

Identifiers9 keys · schema.org snippet

AsOf ID: ent_gilead-sciences
Wikidata: Q663596
X: GileadSciences
website: www.gilead.com
SEC CIK: 0000882095
fiscal year end: 12-31
SIC industry: Biological Products, (No Diagnostic Substances) (2836)
incorporated in: DE
ticker: GILD

Cite this record in schema.org

"sameAs": ["https://www.wikidata.org/wiki/Q663596", "https://asof.is/record/gilead-sciences"],
"identifier": { "@type": "PropertyValue", "propertyID": "asof", "value": "ent_gilead-sciences" }

Paste into the entity's JSON-LD. Why and how.

Sources on this entity2 sites · 541 citations

sec.govprimary · 537

537 claims on record, 25 currently valid, 512 superseded. Last change 2026-10-23.

quarterly net income	2,429,000,000 United States dollar 2026-09-30sec.gov: 1 source for quarterly net income, claim clm_4B6581046BE2	2026-09-30	0.95	sec.gov: 1 source for quarterly net income, claim clm_4B6581046BE2
quarterly operating income	3,462,000,000 United States dollar 2026-09-30sec.gov: 1 source for quarterly operating income, claim clm_8490C244F9F5	2026-09-30	0.95	sec.gov: 1 source for quarterly operating income, claim clm_8490C244F9F5
quarterly research and development	1,101,000,000 United States dollar 2020-03-31sec.gov: 1 source for quarterly research and development, claim clm_46B555B900FF	2020-03-31	0.95	sec.gov: 1 source for quarterly research and development, claim clm_46B555B900FF
quarterly revenue	2026-09-30sec.gov: 1 source for quarterly revenue, claim clm_64E20B8C7E0A	2026-09-30	0.95	sec.gov: 1 source for quarterly revenue, claim clm_64E20B8C7E0A
research and development	2019-12-31sec.gov: 1 source for research and development, claim clm_EF2F795524C5	2019-12-31	0.95	sec.gov: 1 source for research and development, claim clm_EF2F795524C5
shares outstanding	2026-10-23sec.gov: 1 source for shares outstanding, claim clm_3ADDE79BC725	2026-10-23	0.95	sec.gov: 1 source for shares outstanding, claim clm_3ADDE79BC725
total equity	2026-09-30sec.gov: 1 source for total equity, claim clm_F5C77DE07AFE	2026-09-30	0.95	sec.gov: 1 source for total equity, claim clm_F5C77DE07AFE